TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8485447

Group type: EXPERIMENTAL
Intervention: Clonidine, 300 micrograms p.o.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dipotassium clorazepate, 0.3 mg.kg‐1 p.o.
Number of subjects: 50
Study: 2894282

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3837
Study: 31449805

Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 152

Group type: COMPARATOR
Intervention: Medications
Number of subjects: 152
Study: 29218767

Group type: EXPERIMENTAL
Intervention: Successful directives
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Unsuccessful directives
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Fluency and connectedness (FC)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Interaction quality
Number of subjects: 197
Study: 26669912

Group type: EXPERIMENTAL
Intervention: GOL 100 mg + placebo (Group 2)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: GOL 50 mg + MTX (Group 3)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: GOL 100 mg + MTX (Group 4)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 444

Group type: COMPARATOR
Intervention: Placebo + MTX (Group 1)
Number of subjects: 444
Study: 24196556

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 100
Study: 22634077

Group type: EXPERIMENTAL
Intervention: Intervention clinicians received educational toolbox, seminars, teleconferences, mini-fellowships, opinion leader visits, clinician-specific feedback, and pay for performance.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Intervention clinicians participated in 17 interventions over 36 months.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Higher self-efficacy scores at baseline.
Number of subjects: 88
Study: 20399985

Group type: EXPERIMENTAL
Intervention: Ziprasidone (20 and 30 mg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Haloperidol (7.5 and 10 mg)
Number of subjects: 58
Study: 18719448

Group type: EXPERIMENTAL
Intervention: 4-day ambulatory continuous lumbar plexus block with 0.2% ropivacaine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 47
Study: 15884026

Group type: EXPERIMENTAL
Intervention: Nurse coaching
Number of subjects: 111

Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 111
Study: 12882611

Group type: EXPERIMENTAL
Intervention: Phonophoresis of ketoprofen gel using continuous ultrasound (1 MHz, 1.5 W/cm2, for 5 minutes)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Phonophoresis of ketoprofen gel using pulsed ultrasound (100 Hz, 20% duty cycle)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham ultrasound with ketoprofen gel
Number of subjects: 26
Study: 10544630

Group type: EXPERIMENTAL
Intervention: Full protective gear
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fatigues (Control)
Number of subjects: 60
Study: 8895048

Group type: EXPERIMENTAL
Intervention: Alpha-glucosidase inhibitor replacing part of sulphonylurea in Group 1 (n = 8)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alpha-glucosidase inhibitor replacing part of insulin in Group 2 (n = 10)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alpha-glucosidase inhibitor added to insulin without changing insulin dose in Group 3 (n = 9)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alpha-glucosidase inhibitor added to sulphonylurea in Group 4 (n = 9)
Number of subjects: 36
Study: 1900686

Group type: EXPERIMENTAL
Intervention: Induced Hypertension Chemotherapy (IHC) using angiotensin II human (TY-10721) with adriamycin (33 mg/m2, day 3), 5-fluorouracil (330 mg/m2/day through day 1 to 3, 8 to 10), and mitomycin C (5 mg/m2, day 8), repeated every 4 weeks.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (non-IHC) receiving the same drugs via ordinary i.v. injection.
Number of subjects: 62
Study: 6807126

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 0
Study: 30979939

Group type: EXPERIMENTAL
Intervention: Increased levels of calprotectin, von Willebrand factor, angiotensinogen, IL8, IL15, IP10, TNFα
Number of subjects: 1778

Group type: EXPERIMENTAL
Intervention: Decreased levels of leptin, heparin cofactor 2, and serum paraoxonase
Number of subjects: 1778

Group type: EXPERIMENTAL
Intervention: Acute phase responses, cellular responses to lipopolysaccharide, neutrophil responses to bacteria, and endothelial responses
Number of subjects: 1778

Group type: EXPERIMENTAL
Intervention: Sepsis-like profile
Number of subjects: 1778
Study: 27894601

Group type: EXPERIMENTAL
Intervention: Erlotinib with ramucirumab (10 mg/kg every 2 weeks and 150 mg daily)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Erlotinib with ramucirumab
Number of subjects: 462

Group type: COMPARATOR
Intervention: Erlotinib with placebo
Number of subjects: 462
Study: 26768436

Group type: EXPERIMENTAL
Intervention: gabapentin + dexamethasone + 5HT3 receptor antagonist
Number of subjects: 413

Group type: COMPARATOR
Intervention: placebo + dexamethasone + 5HT3 receptor antagonist
Number of subjects: 413
Study: 25051811

Group type: EXPERIMENTAL
Intervention: Structured pharmaceutical counseling training
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no structured training)
Number of subjects: 56
Study: 21508859

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19153374

Group type: EXPERIMENTAL
Intervention: High-dose vitamin supplementation (pyridoxine, cobalamin, and folic acid)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Low-dose vitamin supplementation (pyridoxine, cobalamin, and folic acid)
Number of subjects: 300
Study: 17214789

Group type: EXPERIMENTAL
Intervention: Intensive, individual educational training on breast cancer screening
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard clinic education on breast cancer screening
Number of subjects: 79
Study: 15545586

Group type: EXPERIMENTAL
Intervention: Intracapsular tonsillectomy using low-temperature plasma excision (n = 27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Total tonsillectomy using conventional electrosurgery (n = 28)
Number of subjects: 55
Study: 16200718

Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel (1.5 mg of 17 beta‐estradiol/d) + micronized progesterone (100 mg/d) in group 1 (G1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel (1.5 mg of 17 beta‐estradiol/d) + medroxyprogesterone acetate (2 mg/d) in group 2 (G2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel (0.75 mg of 17 beta‐estradiol/d) + micronized progesterone (100 mg/d) in group 3 (G3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel (0.75 mg of 17 beta‐estradiol/d) + medroxyprogesterone acetate (2 mg/d) in group 4 (G4)
Number of subjects: 60
Study: 9029746

Group type: EXPERIMENTAL
Intervention: Activated charcoal administered immediately after pholcodine (25 g)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Activated charcoal administered 2 hours after pholcodine (25 g)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Activated charcoal administered 5 hours after pholcodine (25 g)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Multiple doses of activated charcoal (10 g every 12 h for 84 h)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Pholcodine administered on an empty stomach with water only (100 mg)
Number of subjects: 4
Study: 8200955

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (15.8 mmol/day) for 4 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3310941

Group type: EXPERIMENTAL
Intervention: 400 mg of administered norfloxacin twice daily for three days
Number of subjects: 209

Group type: COMPARATOR
Intervention: 800 mg of sulfamethoxazole and 160 mg of trimethoprim administered twice daily for ten days
Number of subjects: 209
Study: 30614004

Group type: EXPERIMENTAL
Intervention: DHA (75 mg of DHA/kg/d for 14 days)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control (high oleic sunflower oil for 14 days)
Number of subjects: 110
Study: 29903984

Group type: EXPERIMENTAL
Intervention: Whey Protein (WP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Maltodextrin (MD)
Number of subjects: 8
Study: 27537926

Group type: EXPERIMENTAL
Intervention: 40 mg lidocaine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 80 mg lidocaine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 160 mg lidocaine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 100 mg lidocaine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 300 mg lidocaine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Temperature discrimination test
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 28
Study: 25364998

Group type: EXPERIMENTAL
Intervention: Caregiving for an ill or dependent family member
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Grandparenting and parenting an adult child
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Death of a loved one
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Redemption and mutual fulfillment as caregivers, reconciliations with adult children, and legacy‐building as grandparents
Number of subjects: 48
Study: 23210199

Group type: COMPARATOR
Intervention: Modified corticotomy-facilitated orthodontic tooth movement alone (Group I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Modified corticotomy-facilitated orthodontic tooth movement combined with bone grafting (Group II)
Number of subjects: 20
Study: 20520288

Group type: EXPERIMENTAL
Intervention: d-amphetamine (40 mg/d)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (0 mg/d)
Number of subjects: 9
Study: 18467316

Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy (CHRT) with 60 Gy, infusional 5-FU (300 mg/m²/day for 6 weeks), and intermittent cisplatin (20 mg/m²/day during weeks 1 and 5) followed by maintenance gemcitabine (1000 mg/m² weekly for 3/4 weeks)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Gemcitabine alone (1000 mg/m² weekly for 7 weeks) followed by maintenance gemcitabine (1000 mg/m² weekly for 3/4 weeks)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy (CHRT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 119
Study: 16321132

Group type: EXPERIMENTAL
Intervention: Tilt-table standing for 30 minutes, three times per week for 12 weeks
Number of subjects: 20
Study: 12865191

Group type: EXPERIMENTAL
Intervention: Oral HRT (oestradiol valerate and medroxyprogesterone acetate)
Number of subjects: 885

Group type: COMPARATOR
Intervention: Dermal HRT (17 beta‐oestradiol gel with oral progestogen)
Number of subjects: 885
Study: 10903586

Group type: EXPERIMENTAL
Intervention: Mobilization with compression
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standardized physical therapy program (Control)
Number of subjects: 30
Study: 8880021

Group type: EXPERIMENTAL
Intervention: 75 mg acetylsalicylic acid
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 160 mg acetylsalicylic acid
Number of subjects: 18

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 18
Study: 1813707

Group type: EXPERIMENTAL
Intervention: Management with vasoactive substances and surgical removal of the focus
Number of subjects: 95

Group type: COMPARATOR
Intervention: Postoperative management
Number of subjects: 95
Study: 6403151

Group type: EXPERIMENTAL
Intervention: Emotional support offered to children and families during the trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participation in the clinical trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selection criteria for participants
Number of subjects: 0
Study: 31474281

Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention (brief in-class writing assignment about personal values)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 820
Study: 29913085

Group type: EXPERIMENTAL
Intervention: TimeStamper software for coding prelinguistic vocalizations in real time
Number of subjects: 0
Study: 27358299

Group type: EXPERIMENTAL
Intervention: Continuous and intermittent feeding regimen
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intermittent feeding regimen
Number of subjects: 26
Study: 24459677

Group type: EXPERIMENTAL
Intervention: Quantic molecular resonance scalpel (QMRS)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Traditional scalpel (TS)
Number of subjects: 85
Study: 22248672

Group type: EXPERIMENTAL
Intervention: Resistance training for 16 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Aerobic training for 16 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 32
Study: 20010070

Group type: EXPERIMENTAL
Intervention: DRV/r monotherapy (800/100 mg once daily)
Number of subjects: 256

Group type: COMPARATOR
Intervention: DRV/r with two nucleoside reverse transcriptase inhibitors (NRTIs)
Number of subjects: 256
Study: 17346436

Group type: EXPERIMENTAL
Intervention: PMBL sublingual treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 41
Study: 16402646

Group type: EXPERIMENTAL
Intervention: Nasal corticosteroids
Number of subjects: 11

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 11
Study: 14582440

Group type: EXPERIMENTAL
Intervention: Trimetazidine and perindopril (combined treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perindopril (6-month therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimetazidine (6-month therapy)
Number of subjects: 0
Study: 10380088

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 2,000 mcg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 400 mcg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8678627

Group type: EXPERIMENTAL
Intervention: Shed mediastinal RBCs
Number of subjects: 26

Group type: COMPARATOR
Intervention: Circulating RBCs
Number of subjects: 26
Study: 2072372

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (64 mmol KCl)
Number of subjects: 24
Study: 6519741

Group type: EXPERIMENTAL
Intervention: High-sodium intake (300 mmol per day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low-sodium intake (50-100 mmol per day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Change in plasma NE between HS and LS periods
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Norepinephrine release
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Forearm blood flow (FBF)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Change in forearm vascular resistance
Number of subjects: 25
Study: 30053212

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 1000 mg × 2 doses at 0, 15 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC) 500 mg/m2 monthly
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 60
Study: 28557736

Group type: EXPERIMENTAL
Intervention: Intervention schools with increased opportunities for risk and challenge (e.g., rough-and-tumble play, reduced rules, added loose parts)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Intervention schools with increased opportunities for risk and challenge
Number of subjects: 840

Group type: COMPARATOR
Intervention: Control schools (no change in play environment)
Number of subjects: 840
Study: 26142924

Group type: EXPERIMENTAL
Intervention: Good-quality photodynamic diagnosis-assisted transurethral resection of bladder tumor (GQ-PDDTURBT)
Number of subjects: 808

Group type: COMPARATOR
Intervention: Good-quality white-light transurethral resection of bladder tumor (GQ-WLTURBT)
Number of subjects: 808
Study: 23912002

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg/day (E20)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esomeprazole 10mg/day (E10)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omeprazole 10mg/day (O10)
Number of subjects: 0
Study: 21114351

Group type: EXPERIMENTAL
Intervention: Accuracy motivation (monetary incentives for accuracy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provided anchors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-generated anchors
Number of subjects: 0
Study: 18395579

Group type: EXPERIMENTAL
Intervention: RIX4414
Number of subjects: 15183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15183
Study: 27812854

Group type: EXPERIMENTAL
Intervention: Tc99m + blue dye (BD)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Number of subjects: 342

Group type: COMPARATOR
Intervention: SLN algorithm (SA)
Number of subjects: 342
Study: 12839279

Group type: EXPERIMENTAL
Intervention: 10 mg zinc daily for 5 days a week for 16 weeks
Number of subjects: 280
Study: 11136297

Group type: COMPARATOR
Intervention: Loratadine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loratadine + ketoconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loratadine + cimetidine
Number of subjects: 0
Study: 9135744

Group type: EXPERIMENTAL
Intervention: Displaced malleolar fractures (mean BMI 28.25 kg/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Undisplaced malleolar fractures (mean BMI 24.58 kg/m2)
Number of subjects: 0
Study: 1590373

Group type: EXPERIMENTAL
Intervention: Lipid study (infusion of lipid emulsion to meet resting energy requirements during 84‐h oral fast)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control study (84 h fasting without lipid infusion)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Both studies (control and lipid)
Number of subjects: 5
Study: 6476319

Group type: EXPERIMENTAL
Intervention: Atropine 0.6 mg intravenously
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.2 mg intravenously
Number of subjects: 40
Study: 31590219

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal framing exercise-related pain as helpful
Number of subjects: 78

Group type: COMPARATOR
Intervention: Cognitive reappraisal framing exercise-related pain as harmful
Number of subjects: 78
Study: 29252842

Group type: EXPERIMENTAL
Intervention: Treadmill training combined with anodal electrode positioned over the primary motor cortex in the region of the dominant hemisphere and the cathode positioned in the supraorbital region contralateral to anode
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Treadmill training combined with the anodal electrode positioned over the primary motor cortex in the region of the injured hemisphere and the cathode positioned contralateral to anode over the primary motor cortex
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham anodal transcranial direct current stimulation over the primary motor cortex and sham cathode over the contralateral supraorbital region combined with treadmill training
Number of subjects: 30
Study: 26242728

Group type: EXPERIMENTAL
Intervention: 3D laparoscopy simulator system
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2D laparoscopy simulator system
Number of subjects: 50
Study: 24930546

Group type: EXPERIMENTAL
Intervention: MOM hip resurfacing system (ReCap)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard MOP total hip arthroplasty (Mallory Head/Exeter)
Number of subjects: 52
Study: 21868372

Group type: EXPERIMENTAL
Intervention: Folinic acid supplementation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 21109132

Group type: EXPERIMENTAL
Intervention: Group B (additional propofol 0.5 mg/kg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Group A (1.5 mg/kg propofol)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Group C (2 mg/kg propofol)
Number of subjects: 102
Study: 17236741

Group type: EXPERIMENTAL
Intervention: Computer-based motivational intervention (20-minute single-session)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Assessment only (Control group)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Computer-based motivational intervention
Number of subjects: 107
Study: 15866550

Group type: EXPERIMENTAL
Intervention: Worst-event challenge
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Avoidance challenge
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Conduct problems (CP)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Post-challenge urinary epinephrine (E) levels
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Cortisol concentrations in saliva
Number of subjects: 335
Study: 12208409

Group type: EXPERIMENTAL
Intervention: Omapatrilat 40 mg/day
Number of subjects: 107

Group type: COMPARATOR
Intervention: Lisinopril 20 mg/day
Number of subjects: 107
Study: 11477887

Group type: EXPERIMENTAL
Intervention: 2RIFATER/4RIFINAH regimen
Number of subjects: 308

Group type: COMPARATOR
Intervention: 2HRZ/4HR
Number of subjects: 308
Study: 8594696

Group type: EXPERIMENTAL
Intervention: IVR 400 micrograms/kg plus DEC 6mg/kg
Number of subjects: 1717

Group type: EXPERIMENTAL
Intervention: IVR 400 micrograms/kg alone
Number of subjects: 1717

Group type: EXPERIMENTAL
Intervention: DEC 6 mg/kg alone
Number of subjects: 1717

Group type: EXPERIMENTAL
Intervention: IVR 400 micrograms/kg plus DEC 3 mg/kg
Number of subjects: 1717

Group type: EXPERIMENTAL
Intervention: IVR 400 micrograms/kg
Number of subjects: 1717
Study: 2706316

Group type: EXPERIMENTAL
Intervention: 20 mg sustained-release methylphenidate (SR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 10 mg immediate-release methylphenidate (IR)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Comparison of SR formulations
Number of subjects: 18
Study: 770081

Group type: EXPERIMENTAL
Intervention: Azapropazone 1200 mg per day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1600 mg per day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Azapropazone
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 41
Study: 31976519

Group type: EXPERIMENTAL
Intervention: 11β‐MNTDC 200 mg daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 11β‐MNTDC 400 mg daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 30642053

Group type: EXPERIMENTAL
Intervention: Vegan meal with tofu (V-meal)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Processed-meat and cheese meal (M-meal)
Number of subjects: 60
Study: 28445600

Group type: EXPERIMENTAL
Intervention: Caplacizumab
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72